Table 2.
Medical therapy at diagnosis and at follow-up.
| Incomplete KD | Complete KD | p-value | |
|---|---|---|---|
| Treatment at baseline | |||
| Dose of IVIG in g/kg | 2 | 2 | |
| IVIG (initial treatment), N (%) | 131 (99.2) | 216 (98.6) | 0.95 |
| 2nd dose of IVIG, nb of patients (%) | 29/125 (23.2) 29/132 (22) |
43/207 (20.7) 43/219 (19.6) |
0.60 0.64 |
| Corticosteroids, nb of patients (%) | 23/132 (17.4) | 28/219 (12.8) | 0.01 |
| Aspirin treatment at diagnosis, N (%) | 131 (99.2) | 216 (98.6) | 0.95 |
| Dose of Aspirin at diagnosis in mg/kg (Median/IQR) | 80 (50-80) | 80 | |
| - VKA (n/%) - Clopidogrel (n/%) - Other (n/%) |
7 (5.3) 2 (1.5) 0 (0) |
1 (0.4) 2 (0.9) 1 (0.4)* |
|
| Treatment at FU | |||
| - Aspirin (n/%) - VKA (n/%) - Clopidogrel (n/%) - Betablocker (n/%) |
20 (15) 4 (3.0) 0 0 |
16 (7.3) 2 (0.9) 1 (0.5) 1 (0.5) |
|
IVIG, intravenous immunoglobulins; IQR, interquartile range; VKA, Vitamin K antagonist; FU, follow up.
*
Enalapril.